Beckley Psytech
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Beckley Psytech was a clinical-stage biopharmaceutical company based in Oxford, England, founded in 2019 by Amanda Feilding and Cosmo Feilding Mellen, building on decades of psychedelic research by the Beckley Foundation. It developed next-generation psychedelic compounds - including psilocybin and 5-MeO-DMT derivatives such as BPL-003 (intranasal mebufotenin benzoate) and ELE-101 - into licensed medicines for neuropsychiatric disorders, chiefly treatment-resistant depression and anxiety. Its lead asset BPL-003 reached Phase 2b, posting positive topline results in July 2025 and FDA Breakthrough Therapy Designation in October 2025. In January 2024 atai Life Sciences made a $50 million strategic investment for a 35.5% stake; in June 2025 the two companies announced a merger completed in November 2025, forming AtaiBeckley.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded in Oxford
Amanda Feilding and Cosmo Feilding Mellen founded Beckley Psytech in Oxford to develop psychedelic compounds into licensed pharmaceuticals for mental health disorders.
- atai Life Sciences strategic investment
In January 2024 atai Life Sciences made a $50 million strategic investment in Beckley Psytech, taking a 35.5% stake with a right of first refusal on any sale and first negotiation rights over BPL-003 and ELE-101.
- Merger with atai Life Sciences
In June 2025 atai Life Sciences and Beckley Psytech announced a strategic all-share merger; it completed in November 2025, creating AtaiBeckley with a combined pipeline of rapid-acting psychedelic therapies.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.